Illumina
21
80M
16
0.81
4
0.24
5
- Stages of investment
- Areas of investment
Summary
Illumina is the famous Corporate Investor, which was founded in 1998. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the San Diego.
The fund was created by David R. Walt, John Stuelpnagel, Larry Bock, Satnam Alag.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Illumina, startups are often financed by IP Group Plc, MVI Finance, HBM Healthcare Investments AG. The meaningful sponsors for the fund in investment in the same round are Sutter Hill Ventures, Yaletown Partners, Warburg Pincus. In the next rounds fund is usually obtained by IP Group Plc, Lansdowne Partners, Invesco.
The top amount of exits for fund were in 2015. This Illumina works on 11 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. Considering the real fund results, this Corporate Investor is 7 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2016.
The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight GRAIL, Oxford Nanopore Technologies, Human Longevity. Among the most popular fund investment industries, there are Wellness, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 21
- Lead investments
- 4
- Exits
- 5
- Rounds per year
- 0.81
- Follow on index
- 0.24
- Investments by industry
- Biotechnology (18)
- Health Care (10)
- Health Diagnostics (9)
- Genetics (8)
- Biopharma (6) Show 17 more
- Investments by region
-
- United States (13)
- United Kingdom (6)
- Canada (2)
- Peak activity year
- 2016
- Number of Unicorns
- 4
- Number of Decacorns
- 4
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 1B
- Group Appearance index
- 0.90
- Avg. company exit year
- 10
- Avg. multiplicator
- 2.71
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cache | 07 May 2024 | Biotechnology, Information Technology, Biopharma | Seed | United States, California, Foster City | |
| Human Longevity | 04 Mar 2014 | Biotechnology, Health Care, Health Diagnostics, Genetics | Early Stage Venture | 80M | United States, California, San Diego |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.